Tenderwize
Zurück zur Suche

Open-house rebate agreement for Betahistine

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Nov 30, 2027 · 461 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Betahistin (ATC-Code nach WHO: N07CA01)

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

62 / 100

Komplexität

58 / 100

Risikofaktoren

Structured data says electronic submission is not allowed, while the notice says communication and transmission occur e...

The notice refers to project-room documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfrist...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Betahistine (ATC code N07CA01).
  • Open-house participation model with contract conclusion available to all interested and eligible pharmaceutical companies during the participation period.
Vollständige Zusammenfassung anzeigen

This is an open-house supply arrangement for non-exclusive pharmaceutical rebate agreements for Betahistine (ATC N07CA01) with AOK PLUS. The procedure is open to all interested pharmaceutical companies that meet the stated participation conditions. No contract value is stated, minimum purchase volumes are not guaranteed, and no individual negotiations or exclusivity apply. Participation documents are available via DTVP, but the extracted procurement documents themselves were not provided for analysis.

Risiken

Structured data says electronic submission is not allowed, while the notice says communication and transmission occur e...

The notice refers to project-room documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfrist...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • The company must have its seat in Germany, another EU Member State, or another EEA Contracting State, as stated in the notice.
  • Local representatives may participate only if they themselves qualify as pharmaceutical companies for the offered medicines.

Auftraggeber

Ort

Erfurt, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE256878834

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Betahistine

Non-exclusive pharmaceutical rebate agreement for medicines containing Betahistine (ATC N07CA01). The lot is described as an open-house model, so any eligible pharmaceutical company may join during the participation period. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volumes are stated. Performance/place of use is Germany, specifically Dresden in Saxony, according to the structured data.

SuppliesFrameworkEU fundedElectronic submission

Ort

Dresden, Germany

Dauer

Jan 2026 - Nov 2027

Kategorie

Pharmaceutical products

Frist

Deadline Nov 30, 2027

Vergabedetails

Veröffentlichungsdatum
23 Nov 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
778877-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3